$BAYN

The article discusses how Trump's policies and China's growing biotech sector are impacting Europe's pharmaceutical industry, leading to a decline in its power. European companies have been struggling with capital market fragmentation, which complicates pricing and trials. The shift in policy and competition may reduce international investor interest in European pharma stocks. Companies that thrive in the US or China may see a competitive edge. As a result, Europe's pharmaceutical landscape may face significant challenges going forward.